[go: up one dir, main page]

WO2008008819A3 - Diagnosis and treatment of neurological inflammation - Google Patents

Diagnosis and treatment of neurological inflammation Download PDF

Info

Publication number
WO2008008819A3
WO2008008819A3 PCT/US2007/073233 US2007073233W WO2008008819A3 WO 2008008819 A3 WO2008008819 A3 WO 2008008819A3 US 2007073233 W US2007073233 W US 2007073233W WO 2008008819 A3 WO2008008819 A3 WO 2008008819A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
diagnosis
neurological
inflammatory
neurological inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073233
Other languages
French (fr)
Other versions
WO2008008819A2 (en
Inventor
Andrew K Ottens
Mark S Gold
Firas H Kobeissy
Kevin Kw Wang
Ronald L Hayes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2008008819A2 publication Critical patent/WO2008008819A2/en
Publication of WO2008008819A3 publication Critical patent/WO2008008819A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Drug abuse (METH and MDMA) animals are showing a pro-inflammatory phenotype similar to that of TBI. Detection of cytokines in neurological injury is shown. Methods of treatment of neurological chemical injury include the use of an anti-inflammatory agents due to the elevation of inflammatory related cytokines.
PCT/US2007/073233 2006-07-11 2007-07-11 Diagnosis and treatment of neurological inflammation Ceased WO2008008819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81987406P 2006-07-11 2006-07-11
US60/819,874 2006-07-11

Publications (2)

Publication Number Publication Date
WO2008008819A2 WO2008008819A2 (en) 2008-01-17
WO2008008819A3 true WO2008008819A3 (en) 2008-12-11

Family

ID=38924132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073233 Ceased WO2008008819A2 (en) 2006-07-11 2007-07-11 Diagnosis and treatment of neurological inflammation

Country Status (1)

Country Link
WO (1) WO2008008819A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2324360T3 (en) 2008-08-11 2018-06-30
US20130029859A1 (en) * 2009-06-19 2013-01-31 Svetlov Stanislav I Biomarker assay of neurological condition
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
CN113156139A (en) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 Determination of groups of subjects
JP2020500508A (en) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
AU2018283348A1 (en) * 2017-06-15 2020-01-02 University Of Geneva IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury
CN114878838A (en) * 2022-06-21 2022-08-09 苏州市广济医院 Biomarker, kit and system for auxiliary diagnosis of schizophrenia
CN118501456B (en) * 2024-04-16 2025-07-11 首都医科大学附属北京天坛医院 Application of reagent for detecting CCL4 expression in preparation of kit for identifying glioma and central nervous system inflammatory diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILDEBRAND F. ET AL.: "Importance of cytokines in the posttraumatic inflammatory reaction", UNFALLCHIRURG, vol. 108, no. 10, 21 September 2005 (2005-09-21), pages 793 - 803, XP019320741 *
WANG C.C. ET AL.: "Array-based multiplexed screening and quantitation of human cytokines and chemokines", JOURNAL OF PROTEOME RESEARCH, vol. 1, no. 4, pages 337 - 343, XP002365507 *

Also Published As

Publication number Publication date
WO2008008819A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008008819A3 (en) Diagnosis and treatment of neurological inflammation
HUE050998T2 (en) Drugs for the treatment of fibrotic diseases
IL181706A0 (en) The treatment of inflammatory disorders and pain
EP1793747A4 (en) Improved ultrasound catheter devices and methods
EP1757220A4 (en) ENDOSCOPE AND ENDOSCOPIC DEVICE
NO20044054L (en) Administration of agents for the treatment of inflammation
EP2043630A4 (en) 6,9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN
DE602005024160D1 (en) SUGAR AND / OR SUGAR ALCOHOLS FOR THE PREVENTION AND / OR TREATMENT OF VAGINAL INFECTIONS
DK3279663T3 (en) USE OF GELSOLIN FOR DIAGNOSIS AND TREATMENT OF INFLAMMATION DISEASES
ITMI20020078A0 (en) DEVICE USABLE IN THE TREATMENT OF RESPIRATORY TRACT DISEASES
EP1813218A4 (en) ULTRASONIC TREATMENT DEVICE, ENDOSCOPE AND TREATMENT METHOD
WO2007038551A3 (en) Use of ibudilast for treating drug and behavioral addictions
EP1804813A4 (en) Formulations and methods for treatment of inflammatory diseases
EP2123301A4 (en) USE OF A THERAPEUTIC AGENT IN DISEASES OF THE URINARY TRACT
HUE047318T2 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
EP2021016A4 (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases
CY2018006I1 (en) THERAPEUTIC FORMULATION OF CLADRIVINE FOR THE THERAPEUTIC TREATMENT OF PLAQUE STICHERONE
WO2009024667A3 (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
IS7444A (en) Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
ITMI20040571A1 (en) MEDICAL EQUIPMENT FOR INTESTINAL AND VAGINAL TREATMENTS
NO20070892L (en) Compositions of N-glycolylneuraminic acid and their use in the treatment of colds.
ZA200609974B (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DK1670482T4 (en) USE OF CICLESONIDE IN THE TREATMENT OF RESPIRATORY DISEASES
EP1744740A4 (en) Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
EP1781685A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812796

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07812796

Country of ref document: EP

Kind code of ref document: A2